علاج داء السكري من النوع الثاني مع السمنة وقصور القلب العرضي مع الكسر القذفي المحفوظ

References

DOI: 10.2337/dc26-S009

In adults with type 2 diabetes, obesity, and symptomatic heart failure with preserved ejection fraction (HFpEF), the glucose-lowering treatment plan should include a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA with demonstrated benefits for HF-related symptoms and reduction in HF events (irrespective of A1C).

In adults with type 2 diabetes, obesity, and symptomatic HFpEF, the glucose-lowering treatment plan should include a GLP-1 RA with demonstrated benefits for HF-related symptoms and/or reduction in HF events (irrespective of A1C).